Advances in biomarkers of resistance to KRAS mutation-targeted inhibitors
Abstract KRAS mutations represent the most common driver genetic alterations in multiple malignant tumors, particularly exerting well-defined oncogenic driver roles in non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. The recent success of KRAS G12C mutation-specif...
Furkejuvvon:
| Váldodahkkit: | , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Springer
2025-10-01
|
| Ráidu: | Discover Oncology |
| Fáttát: | |
| Liŋkkat: | https://doi.org/10.1007/s12672-025-03569-x |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|